Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings - Candlesense
GTHP Funding

Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTC:QB GTHP), the maker of the LuViva Advanced Cervical Scan, announced that on August 14th 2025, it had received a payment of $70,000 from its new distribution partner in China, Hangzhou Dongye Medical Technology Company, Ltd. (HDMT). This is the second scheduled payment in a series of nine payments that will total $700,000 in exchange for LuViva components and services. Thus far a total of $100,000 has been received by GTHP.

Related Questions

How will the $70,000 payment and the remaining scheduled payments affect Guided Therapeutics' cash position and runway? What revenue growth can be expected from the new Chinese distribution partnership for the LuViva Advanced Cervical Scan? How does this funding round compare to recent capital raises by peer companies in the cervical cancer screening space, and what implications might it have for the stock valuation?
Find similar articles on Candlesense businesswire